Kiniksa Pharmaceuticals International (KNSA) EV to CFO (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported EV to CFO for 9 consecutive years, with 200.24 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO rose 53.04% year-over-year to 200.24; the trailing twelve-month figure through Jun 2026 stood at 51.09 (down 6.94% YoY), and the FY2025 full-year result was 42.69, down 58.31% from the prior year.
• EV to CFO grew to 200.24 in Q2 2026 per KNSA's latest filing, from 138.03 in the prior quarter.
• Across five years, EV to CFO topped out at 607.98 in Q1 2024 and bottomed at 1456.78 in Q3 2024.
• Historically, EV to CFO has averaged 9.07 across 5 years, with a median of 127.57 in 2023.
• The sharpest annual moves came in 2023 and 2024: EV to CFO jumped 419.78% in 2023, then sank 1246.01% in 2024.
• Over 5 years, EV to CFO stood at 163.99 in 2022, then surged by 419.78% to 524.42 in 2023, then sank by 73.28% to 140.13 in 2024, then declined by 22.01% to 109.29 in 2025, then surged by 83.22% to 200.24 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 200.24, 138.03, and 109.29 for Q2 2026, Q1 2026, and Q4 2025 respectively.